Trial Profile
Neutrophil-To-Lymphocyte Ratio as a predictive biomarker in patients with non small cell lung cancer who are treated with nivolumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer